- Home
- MDBH vs ARMP Comparison
MDBH vs ARMP Comparison
Compare MDBH & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDBH
- ARMP
- Stock Information
- Founded
- MDBH 1997
- ARMP 2016
- Country
- MDBH United States
- ARMP United States
- Employees
- MDBH N/A
- ARMP N/A
- Industry
- MDBH
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDBH
- ARMP Health Care
- Exchange
- MDBH Nasdaq
- ARMP Nasdaq
- Market Cap
- MDBH N/A
- ARMP 73.8M
- IPO Year
- MDBH 2023
- ARMP N/A
- Fundamental
- Price
- MDBH $6.16
- ARMP $1.40
- Analyst Decision
- MDBH
- ARMP Strong Buy
- Analyst Count
- MDBH 0
- ARMP 1
- Target Price
- MDBH N/A
- ARMP $7.00
- AVG Volume (30 Days)
- MDBH 2.8K
- ARMP 15.2K
- Earning Date
- MDBH 05-12-2025
- ARMP 03-20-2025
- Dividend Yield
- MDBH N/A
- ARMP N/A
- EPS Growth
- MDBH N/A
- ARMP N/A
- EPS
- MDBH N/A
- ARMP N/A
- Revenue
- MDBH $1,937,885.00
- ARMP $5,174,000.00
- Revenue This Year
- MDBH N/A
- ARMP $8.43
- Revenue Next Year
- MDBH N/A
- ARMP N/A
- P/E Ratio
- MDBH N/A
- ARMP N/A
- Revenue Growth
- MDBH N/A
- ARMP 14.24
- 52 Week Low
- MDBH $5.78
- ARMP $1.58
- 52 Week High
- MDBH $12.00
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- MDBH 38.62
- ARMP 37.28
- Support Level
- MDBH $6.33
- ARMP $1.58
- Resistance Level
- MDBH $6.52
- ARMP $1.81
- Average True Range (ATR)
- MDBH 0.10
- ARMP 0.14
- MACD
- MDBH -0.03
- ARMP -0.04
- Stochastic Oscillator
- MDBH 0.00
- ARMP 12.50
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.